Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (TSX: BHC )

7.860 +0.030 (+0.38%)
Streaming Delayed Price Updated: 10:44 AM EDT, Aug 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39,210
Open 7.830
Bid (Size) 7.850 (5)
Ask (Size) 7.860 (3)
Prev. Close 7.830
Today's Range 7.820 - 7.920
52wk Range 5.450 - 15.43
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Announces Second Quarter 2024 Results
Via ACCESSWIRE

Performance

YTD
-24.06%
-24.06%
1 Month
-24.57%
-24.57%
3 Month
-12.08%
-12.08%
6 Month
-32.42%
-32.42%
1 Year
-31.41%
-31.41%

More News

Read More
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Bausch Health Announces First Quarter 2024 Results
Via ACCESSWIRE
Salix Announces 2024 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
Court of Appeals for the Federal Circuit Issues Ruling in Norwich Case that Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan
Via ACCESSWIRE
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Based on a New Survey, More Than Half of Surveyed IBS/CIC Patients Feel Alone in Their Experience but Also Find That Social Media Helps Create a Community and Inspires Healthcare Provider Conversations
Via ACCESSWIRE
Salix Pharmaceuticals Announces a Phase 2 Investigator-Initiated Study of RELISTOR(R) (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma
Via ACCESSWIRE
New Survey Finds More Than Half of Past U.S. Colonoscopy Patients Wish They Had Known More Information About Colonoscopies Including Prep Medication Options and How To Prepare for the Procedure
Via ACCESSWIRE
Bausch Health Companies to Present at Cowen Annual Health Care Conference
Via ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Via ACCESSWIRE
Bausch Health Announces Board Refreshment
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.